Skip to main content


28.03.2019 Press releases

MedImpact's Steven Avey receives AMCP Foundation's highest award.

Avey honored for groundbreaking work that has improved countless lives, changed pharmacy benefit management

SAN DIEGO, CA (03/28/2019) — MedImpact, an independent pharmacy benefit manager that puts clients and consumers first, today announced that Steven G. Avey, MS, RPh, FAMCP, has been awarded the Academy of Managed Care Pharmacy (AMCP) Foundation’s most prestigious award, honoring his work to reduce costs and improve health outcomes through pharmacy benefit management.

The award was presented on March 27 during AMCP’s Annual Meeting in San Diego, California.


“I am humbled to receive this award. This would not have been possible without an entire team of talented people who have committed their careers to improving healthcare. To me, this award goes to them.”


Avey served in leadership roles at AMCP from 1998 to 2005. During that time, Avey, working with a dedicated team, developed innovative guidelines for assessing whether new medications should be included in drug formularies. Within five years, he and the team’s groundbreaking approach was adopted by health plans, government agencies and programs, pharmaceutical companies and other industry stakeholders. His work in this area helped to transform formulary management, reducing drug costs and improving care for consumers.

"Steve has long been a guiding light in managed care pharmacy," says Paula J. Eichenbrenner, MBA, CAE, Executive Director of the AMCP Foundation. "We can think of few people who have had as profound an impact on the industry, and we are thrilled to present this award to him."

For the past six years, Avey has been a leader at MedImpact, helping the company develop innovative approaches to managing specialty pharmacy programs that people with the most costly and complex chronic conditions rely on every day. He continues to be an active member of AMCP.

“Those of us who have had the privilege of working with Steve understand that his passion really isn’t for formularies or managing benefits — it’s for improving the lives of people,” said Greg Watanabe, President and Chief Operating Officer. “He has never forgotten what is truly important, and he is a role model for all of us.”


About MedImpact

MedImpact is the PBM that puts clients and consumers first. For more than 30 years, it has had a single mission: To make pharmacy benefits affordable, understandable, and honest. Today, MedImpact’s team and technology serve many of the largest employers and plans, and more than 55 million consumers in the US and around the world. Learn more at or follow us on Twitter @MedImpact.

Read on.
Keep up to date on the latest in the industry.
Client news
National prescription drug take back day helps fight drug abuse.
+5,400 tons. That’s how much the DEA has collected of expired, unwanted or unused prescription medications over the past nine years through the National Prescription Drug Take Back Day program.
Client news
Dispelling the myth: generics are not always low cost.
When we hear the terms “generic” or “off-brand,” we typically think that the product would be a significantly cheaper alternative than the name brand. Well, when it comes to generic drugs, that’s not always in the case. Here are five facts plan sponsors should know:
Client news
FDA approves first and only treatment for common mutation in advanced breast cancer.
The FDA approved a new drug that is a potential game changer for advanced breast cancer patients. Piqray (alpelisib) gained approval on May 24 for treatment of postmenopausal women and men with one of the most commonly mutated genes in advanced or metastatic breast cancer.

Ready for clarity from your PBM?